Franklin Templeton Investments related stories
All articles and analysis
LimeBike raises $50 mln in Coatue-led roundSan Mateo, California-based LimeBike, provider of a dockless bike-sharing service, announced it has raised a $50 million Series B round of funding. Coatue Management led the round, which also included GGV Capital, Franklin Templeton Investments, Section 32, AME Cloud Ventures and the Stanford-StartX Fund, as well as previous investors Andreessen Horowitz and DCM Ventures. As part of the funding, Coatue Partner Thomas Laffont has joined the board of directors. LimeBike has now raised $62 million in total funding.
- Singapore B2B robo-adviser platform Bambu grabs funding
Singapore-based Bambu, a B2B robo-adviser platform provider, has secured an undisclosed amount of funding. The investors were Franklin Templeton Investments, Wavemaker Partners and Robby Hilkowitz.
- Turkish discount retailer Sok plans 2018 IPO, say sources: Reuters
Turkish discount retailer Sok is planning an initial public offering in 2018, sources told Reuters, the latest sign that Turkey's once-moribund IPO market may be coming back to life.
- California pension fund is latest to scrap some active managers: Reuters
A California pension fund has fired Franklin Templeton Investments, JPMorgan Chase & Co and Pacific Investment Management Co from some portfolio-management responsibilities in a shakeup that puts more of its assets in lower-fee, index-tracking investments, the fund said.
- VC-backed Crispr Therapeutics raises $56 mln for IPO
Crispr Therapeutics, a provider of gene-editing technology, has debuted its IPO after pricing its 4 million shares at $14 per share. The stock began trading October 19, 2016 on the NASDAQ under the ticker symbol "CRSP." Citigroup, Piper Jaffrey and Barclays are serving as the lead underwriters. Crispr's backers included Franklin Templeton Investments, New Leaf Venture Partners, Clough Capital Partners LP and Wellington Capital Management LLP.
- True North Therapeutics nabs $45 mln Series D
South San Francisco-based True North Therapeutics, a clinical-stage biopharmaceutical company, has closed $45 million in Series D funding. The investors included HBM Healthcare Investments, Redmile Group, Perceptive Advisors and Franklin Templeton Investments.
- Crispr Therapeutics raises $38 mln
Crispr Therapeutics said June 24 that it raised another $38 million in Series B financing, which closes the round at nearly $140 million. Participating investors in this round include Franklin Templeton Investments, New Leaf Venture Partners, funds advised by Clough Capital Partners LP and Wellington Capital Management LLP, and other undisclosed funds specializing in life sciences. Crispr is a biopharmaceutical company.
- Crispr Therapeutics raises $38 mln
Crispr Therapeutics said June 24 that it raised another $38 million in Series B financing, which closes the round at nearly $140 million. Participating investors in this round include Franklin Templeton Investments, New Leaf Venture Partners, funds advised by Clough Capital Partners LP and Wellington Capital Management LLP, and other undisclosed funds specializing in life sciences. Crispr is a biopharmaceutical company.
Private Equity Jobs of the Week: Blackstone, GE Digital, Franklin Templeton are hiringOpportunities this week include vice president positions at Blackstone's BAAM Ventures and Franklin Templeton Real Asset Advisors, as well as a senior associate job at GE Digital.
Lumira Capital joins G1 Therapeutics' $47 mln Series C roundG1 Therapeutics Inc has raised US$47 million in a Series C financing. The round was led by Cormorant Asset Management with participation from new and existing investors, including Canadian life sciences venture capital firm Lumira Capital. Lumira also invested in the company's Series B round /canada/2015/2/lumira-capital-invests-in-33-mln-series-b-funding-of-g1-therapeutics/ in early 2015. Based in Research Triangle Park, North Carolina, G1 Therapeutics is a developer of novel, small-molecule therapies that help address unmet needs in people with cancer. It plans to use funds raised to advance the clinical development of its lead drug candidate and compound, and grow its pipeline in multiple oncology indications.